Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  DNA damage >  PARP inhibitors >  PF-01367338

PF-01367338

Basic information Safety Supplier Related

PF-01367338 Basic information

Product Name:
PF-01367338
Synonyms:
  • PF01367338 phosphate
  • Rucaparib (AG-014699,PF-01367338) phosphate
  • Rucaparib (AG-014699) phosphate
  • AG014699;RUCAPARIB PHOSPHATE
  • Rucaparib (phosphate)(AG-014699,PF-01367338)
  • Rucaparib phosphate salt
  • Rucaparib phosphate (AG-14699, PF-01367338)
  • CS-47
CAS:
459868-92-9
MF:
C19H21FN3O5P
MW:
421.37
Product Categories:
  • Inhibitors
  • Inhibitor
  • Amines
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
Mol File:
459868-92-9.mol
More
Less

PF-01367338 Chemical Properties

Melting point:
>173°C (dec.)
storage temp. 
Sealed in dry,Room Temperature
solubility 
Soluble in DMSO (up to 25 mg/ml).
form 
Yellow solid.
color 
Yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
More
Less

PF-01367338 Usage And Synthesis

Description

Rucaparib phosphate (459868-92-9) is a potent (Ki<5 nM) PARP1 inhibitor.1?Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2?Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3?Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel,3 and temozolomide.4?Ameliorates the cardiotoxicity of doxorubicin.5?Recently approved for human use by the FDA.

Uses

PARP inhibitor oncolytic

in vivo

Rucaparib (AG014699) phosphate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) phosphate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) phosphate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) phosphate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) phosphate has greatest antitumor effect with three complete regressions[2].
Rucaparib phosphate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].

Animal Model:Female athymic nude mice, implanted SW620 colorectal tumor cells (1 × 107 cells per animal) s.c.[1]
Dosage:0.1 mg/kg in combination with Temozolomide (p.o., 200 mg/kg), 0.05, 0.15, and 0.5 mg/kg in combination with Temozolomide (p.o., 68 mg/kg) or 10 mg/kg
Administration:IP, single dose for 0.1 mg/kg and 10 mg/kg, five daily doses for 0-0.5 mg/kg
Result:Significantly increased Temozolomide toxicity, showed outstanding chemosensitization potency and caused enhancement of Temozolomide-induced tumor growth delay
Animal Model:CD-1 nude mice bearing established Capan-1 xenografts[2]
Dosage:10 mg/kg or 50, 100 and 150?mg/kg
Administration:IP for 10 mg/kg; PO for 50, 100 and 150?mg/kg, single dose (Pharmacokinetics)
Result:Parent drug was detectable in the plasma only at 30?min after 10?mg/kg i.p and up to 4?h for 50–150?mg/kg p.o.. Was still detectable in most mice receiving oral rucaparib at 3 days. Does not easily cross the plasma membrane.
Animal Model:CD-1 nude mice bearing established Capan-1 xenografts[2]
Dosage:10?mg/kg i.p. daily for 5 days per week for 6 weeks, 50 or 150?mg/kg p.o. daily × five weekly × six, 150?mg/kg p.o. once per week for 6 weeks or three times per week for 6 weeks, or 150?mg/kg p.o. daily for five days every 3 weeks
Administration:IP or PO
Result:10?mg/kg i.p. significantly inhibited the growth of the tumor, daily oral administration at 150?mg/kg had an equivalent effect on tumor growth to 10?mg/kg i.p.. The schedule with the greatest antitumor effect was oral administration of 150?mg/kg on a once weekly schedule with three complete regressions.
Animal Model:CD-1 nude mice, NB1691 and SHSY5Y xenografts[6]
Dosage:1 mg/kg
Administration:IP, daily for 5 d in combination with Temozolomide (orally daily ×5 at a dose of 68 mg/kg)
Result:Enhanced the antitumor activity of Temozolomide and indicated complete and sustained tumor regression.

IC 50

PARP-1: 1.4 nM (Ki); PARP-2; PARP-3

References

[1] HUW D THOMAS. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.[J]. Molecular Cancer Therapeutics, 2007, 6 3: 945-956. DOI:10.1158/1535-7163.mct-06-0552
[2] YVETTE DREW. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.[J]. JNCI Journal of the National Cancer Institute, 2011, 103 4: 334-346. DOI:10.1093/jnci/djq509
[3] MAIKE IHNEN. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.[J]. Molecular Cancer Therapeutics, 2013, 12 6: 1002-1015. DOI:10.1158/1535-7163.mct-12-0813
[4] RUTH PLUMMER. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.[J]. Cancer Chemotherapy and Pharmacology, 2013, 71 5: 1191-1199. DOI:10.1007/s00280-013-2113-1
[5] MAJID ALI. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.[J]. Molecular Cancer Therapeutics, 2011, 10 12: 2320-2329. DOI:10.1158/1535-7163.mct-11-0356

PF-01367338Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Email
sales@jingyan-chemical.com
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
More
Less

PF-01367338(459868-92-9)Related Product Information